Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517516 | 0.93 | CETP (0.42) | CETPSSTR5KCNH2GCGRTRPV1 | |
| SCHEMBL4508924 | 0.89 | GCGR (0.33) | CETPGCGR | |
| SCHEMBL4502681 | 0.88 | CETP (0.35) | CETPSSTR5KCNH2 | |
| SCHEMBL11938632 | 0.86 | CETP (0.36) | CETPSSTR5KCNH2TRPV1 | |
| SCHEMBL4715648 | 0.85 | CETP (0.36) | CETPSSTR5KCNH2 | |
| SCHEMBL4511585 | 0.83 | CETP (0.42) | CETPGCGR | |
| SCHEMBL4501187 | 0.83 | CETP (0.37) | CETPTRPV1 | |
| SCHEMBL4511591 | 0.83 | CETP (0.42) | CETPGCGR | |
| SCHEMBL4514631 | 0.83 | CETP (0.42) | CETPGCGR | |
| SCHEMBL4510672 | 0.82 | CETP (0.39) | CETPKCNH2GCGRTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2007107243-A1 | SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | CYP46A1, CBX3, CDYL | CETP 108/4885SSTR5 3759/4885KCNH2 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.